Article Text

Risk factors influencing the prescription of tiotropium Respimat formulation: a population-based cohort study
  1. Francesco Trotta1,2,
  2. Roberto Da Cas2,
  3. Maja Rajevic3,
  4. Mariangela Rossi4,
  5. Giuseppe Traversa2
  1. 1Pharmacovigilance Office, Italian Medicines Agency, Rome, Italy
  2. 2Pharmacoepidemiology Unit, National Centre for Epidemiology, Italian National Institute of Health, Rome, Italy
  3. 3Pharmaceutical Sciences, Drug Chemistry and Technologies Department, “La Sapienza” University, Rome, Italy
  4. 4Unit for Pharmaceutical Governance, General Directorate for Health, Umbria Region, Perugia, Italy
  1. Correspondence to Dr Francesco Trotta; f.trotta{at}aifa.gov.it

Abstract

Objectives The study aims at investigating the influence of several factors on the probability of receiving one of the two tiotropium formulations (Respimat or Handihaler).

Design Drug utilisation study.

Setting All residents in the Region Umbria, Italy, aged ≥45 years, who received prescriptions of tiotropium during 2011–2012.

Participants Two groups of patients were studied: (1) incident users of the two tiotropium formulations (ie, without tiotropium prescriptions in the previous 6 months); (2) switchers from Handihaler to Respimat. Users of the two formulations were compared with regard to baseline characteristics and medical history. The adjusted OR of receiving Respimat was estimated for several factors.

Results Incident users of the two formulations (4390 participants) had similar characteristics. They were older and with more comorbidities than patients included in randomised control trials (RCTs). Among prevalent users of Handihaler, the probability of switching to Respimat was greater in patients with severe respiratory disease (users of ≥4 respiratory drugs: adjusted OR=4.62; 95% CI 2.46 to 8.69) and among β-blocker users (adjusted OR=1.76; 95% CI 1.13 to 2.75). Age above 75 years and lipid-lowering drug use reduced the probability of switching. A positive association was also found between neurological conditions and the use of Respimat.

Conclusions When starting tiotropium treatment, the choice between the two formulations is weakly affected by comorbidities and chronic obstructive pulmonary disease severity. Instead, these characteristics influence the likelihood of switching from Handihaler to Respimat. Since tiotropium users in clinical practice are more severe than those included in RCTs, further aetiological studies are needed to compare the safety profile of the two formulations in routine care.

  • RESPIRATORY MEDICINE (see Thoracic Medicine)
  • CLINICAL PHARMACOLOGY

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Supplementary materials

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.